Hospital, patients who had mitral valve repair lived longer than those who had valve replacement and freedom from reoperation was similar ( Figure 1) . (6) One further advantage of valvuloplasty is that, if and when reoperation is needed, it can usually be performed with mortality similar to that of primary surgery. 
tion.
(1) On the other hand, degeneration of bioprostheses limits durability and requires multiple reoperations, especially in younger patients. In addition, the mortality rate of reoperations is higher than that of primary surgery. It varies with the pathology, the condition of the patient and the experience of the surgical team, but ranges from 3% to 10% in most reports. (2, 3) All these complications are even more frequent in rheumatic populations, characterised by a low mean age and poor socioeconomical conditions, which makes adherence to anticoagulation poor and follow-up difficult. (4, 5) Hence, it is in these populations where the alternative of valve repair, especially of the mitral valve, would have the greatest benefit. Unfortunately, the results of mitral valvuloplasty in rheumatic mitral regurgitation are not as good as those observed in degenerative mitral regurgitation. 
tecHnIque oF MItrAl vAlve rePAIr
The mitral apparatus is a complex structure. It is composed of leaflets, chordae tendineae and papillary muscles, and even the Because of this complex anatomic pathology of the valve, repair may be complex and obliges to at least correction of the leaflet prolapse and remodelling and/or size reduction of the annulus ( Figure 2 ). With regards to the latter, it is now assumed that the annular dilation may not be just functional but also caused by the disease itself. (11) In fact, the annulus loses its capacity to contract and acquires an abnormal shape which needs to be restored to normal. Finally, dilatation of the mitral annulus was always believed to occur in its posterior segment, the anterior segment being relatively protected from enlargement, but there is recent evidence that the anterior annulus can also dilate. (12) Correction of the anterior leaflet prolapse, as initially proposed by Carpentier, is achieved by shortening of the chordae tendineae using one or more of several techniques, of which one of the most frequent was the opening of a trench in the corresponding head of the papillary muscle and burying the excess-length segment of the chordae. (10) This has proven to be one of weakest points of the valvuloplasty, especially in rheumatic cases, as the chordae tendineae continue to elongate due to progression of the disease.
For this reason, I and others have for more than a decade now preferred the replacement/reinforcement of the chordae using artificial chordae made of GoreTex sutures (PTFE-polytetrafluorethylene). This method has proven much more durable and reproducible. (13) Treatment of the annular dilatation is most frequently done by implantation of an annuloplasty ring. Initially, there were two devices based on two different concepts: the rigid (Carpentier) and the flexible ring (Duran) . (10, 14) Both 
Importantly, the procedure must end with a perfectly competent valve. Even relatively minor degrees of residual regurgitation observed on the operating table tend to be much greater in real physiological conditions. Hence the value of intra-operative transoesophageal echocardiography, which is currently mandatory in any operation suite where these procedures are performed, is proved. Transoesophageal echocardiography has not only permitted the immediate assessment of the results, allowing correction if necessary, but also helped surgeons to better understand the anatomy and physiology of the mitral valve.
MITRAl vAlvE REpAIR
FIGure 2: Repair of mitral valve regurgitation may be complex and often requires the association of several techniques involving the leaflet, the chordate tendineae, the papillary muscles and the annulus: a) chordal shortening; b) chordal transposition; c) leaflet resection; d) posterior leaflet chordal resection; e:)commissurotomy; f) chordal/papillary muscle division; g) chordal fenestration; h) ring annuloplasty.
results
The techniques of mitral valve repair in rheumatic disease are, therefore, more complex and more difficult to master than in nonrheumatic cases, especially in the case of isolated prolapse of the mid-scallop of the posterior leaflet (P2). The resulting learning curve (18) (Figure 3 ) has led many surgeons to give up early in this regard. Even some experienced repair surgeons have questioned the reparability of rheumatic valves in these young patient population groups. (19) One of the main characteristics, impacting on the results of repair of rheumatic mitral regurgitation, is that the disease is progressive and, continues even after repair. The progression of the histopathological rheumatic process inevitably leads to scarring with retraction of the leaflets and subvalvular apparatus which render the valve both stenotic and incompetent and eventually will lead to reoperation, most often to replace the valve (Figure 4 ). This progression of the disease, however, has significantly different consequences than those after failure of a prosthesis used for replacement. Only rarely, does the disease evolve so rapidly that it does not permit timely re-intervention. There is usually time for an adequate diagnosis and elective reoperation which, as indicated above, carries mortality similar to that of primary procedures. Hence valve-related mortality is much lower than after valve replacement. (20) In general, the survival free from cardiac or valve-related death is in excess of 90% after five years. In my own experience in the young rheumatic population, approximately 16% of the patients required reoperation after a mean follow-up of 6 years (21) ( Figure 5 ). In these cases, most of the valves had mixed stenosis and regurgitation and valve failure was mostly associated with the shortening of chordae, need for commissurotomy and implantation of a Carpentier ring at the initial procedure. Freedom from valve-related mortality and from valve-related complications was 96% and 80%, respectively, after 6 years of follow-up. The survival complication-free was significantly worse (72%) in patients aged 12 years or less, as compared with that observed in patients older than 12 years (82%).
These results, observed from my own follow-up of the patients, were later confirmed in the same study-population, in a study published by Skoularigis et al., which showed a global survival of 76% and an event-free survival of 84% after a minimum of 9 years of follow-up. reported on 278 children, with a mean age 11.7 years, who were followed for a mean of 56.5 months. The actuarial, reoperation-free and event-free survivals were 95%, 92% and 56%, respectively. 
